Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 6-10 million people worldwide[1]. The disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to the cardinal motor symptoms of tremor, bradykinesia, rigidity, and postural instability[2]. Additionally, non-motor symptoms including autonomic dysfunction, sleep disorders, cognitive impairment, and psychiatric manifestations significantly impact patient quality of life[3].
The treatment of Parkinson's disease has evolved dramatically since the introduction of levodopa in the 1960s. Contemporary management focuses on symptomatic control of motor and non-motor symptoms, minimizing motor complications, and ultimately developing disease-modifying therapies that can slow or halt neurodegeneration[4]. This comprehensive overview examines current treatment approaches across all categories.
Levodopa (L-3,4-dihydroxyphenylalanine) remains the most effective symptomatic treatment for PD and is considered the gold standard for motor symptom management[5]. As the metabolic precursor of dopamine, levodopa crosses the blood-brain barrier and is decarboxylated to dopamine in the central nervous system[6].
Formulations:
Dosing: Typically initiated at 25/100 mg (carbidopa/levodopa) three times daily and titrated based on response. Maintenance doses usually range from 300-1000 mg of levodopa daily in divided doses[10].
Adverse effects: Nausea, vomiting, hypotension, hallucinations, and motor fluctuations (wear-off, on-off phenomena)[5:1]. Long-term use is associated with dyskinesias, particularly with high doses and long disease duration.
Dopamine agonists directly stimulate dopamine receptors, providing symptomatic relief without the need for dopamine conversion. They are commonly used as first-line therapy in younger patients or as adjuncts to levodopa in advanced disease[11].
Oral dopamine agonists:
Adverse effects: Nausea, vomiting, somnolence, impulse control disorders (pathological gambling, shopping, eating), hallucinations, and peripheral edema.
MAO-B inhibitors block the enzymatic breakdown of dopamine in the brain, extending the duration of levodopa effect and providing modest symptomatic benefit as monotherapy in early disease[14].
Available agents:
Adverse effects: Headache, nausea, insomnia, confusion, and potential for tyramine interaction (minimal with recommended doses).
Catechol-O-methyltransferase (COMT) inhibitors block the peripheral breakdown of levodopa, increasing its plasma half-life and CNS availability[17].
Agents:
Originally developed as an antiviral agent, amantadine provides modest antiparkinsonian effects and is uniquely effective in reducing levodopa-induced dyskinesias.
Deep brain stimulation (DBS) is the most effective surgical treatment for advanced PD, significantly improving motor symptoms and reducing medication requirements[19].
Targets[20]:
Eligibility criteria[21]:
Outcomes[22]:
| Agent | Mechanism | Phase | Status |
|---|---|---|---|
| Prasinezumab | Anti-α-synuclein antibody | Phase 2 | Roche |
| BIIB122 (DNL151) | LRRK2 inhibitor | Phase 2b | Biogen/Denali |
| ACI-7104 | α-synuclein vaccine | Phase 1 | AC Immune |
| Venglustat | GCase modulator | Phase 2 | Sanofi |
Alpha-synuclein aggregation is a central pathogenic mechanism in PD, making it an attractive therapeutic target. Immunotherapies including active vaccination and passive antibody therapy are in various trial stages[11:1].
LRRK2 (leucine-rich repeat kinase 2) mutations are the most common genetic cause of PD, making LRRK2 inhibitors promising disease-modifying agents.
Glucocerebrosidase (GBA) mutations are the most significant genetic risk factor for PD. GCase modulators are under investigation.
Exercise is increasingly recognized as a disease-modifying intervention in PD[4:1]:
For detailed treatment algorithms and comprehensive therapeutic approaches, see Parkinson's Disease Treatment.
The treatment of Parkinson's disease has advanced considerably, offering patients multiple therapeutic options to manage motor and non-motor symptoms effectively. While levodopa remains the cornerstone of treatment, the availability of dopamine agonists, MAO-B inhibitors, COMT inhibitors, and device-based therapies provides flexibility in managing the complex needs of PD patients.
The future of PD treatment lies in disease-modifying therapies targeting α-synuclein aggregation, LRRK2 inhibition, and other pathogenic mechanisms. Comprehensive care incorporating pharmacological, surgical, lifestyle, and supportive approaches remains essential for optimizing outcomes.
Pablo-Fernandez GD, et al. Global, regional, and national burden of Parkinson's disease, 1990-2021. Lancet Neurology. 2024. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008. ↩︎
Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020. ↩︎ ↩︎
Fahn S. How do you treat motor complications in Parkinson's disease?. J Neurol. 2005. ↩︎ ↩︎
Nutt JG, et al. The pharmacology of levodopa. Handb Clin Neurol. 2014. ↩︎
Stocchi F, et al. COMT inhibitors for Parkinson's disease. Expert Opin Pharmacother. 2015. ↩︎
Brooks DJ, et al. Enteral levodopa/carbidopa gel infusion for Parkinson's disease. Expert Opin Pharmacother. 2014. ↩︎
Olanow CW, et al. Continuous subcutaneous levodopa delivery for Parkinson's disease. Mov Disord. 2020. ↩︎
Poewe WH, et al. Diagnosis and management of Parkinson's disease in adults. Pract Neurol. 2020. ↩︎
Schapira AHV, et al. Therapeutic advances in Parkinson's disease. Mov Disord. 2019. ↩︎ ↩︎
Hubble JP, et al. Pramipexole in Parkinson's disease. Neurology. 2000. ↩︎
Adler CH, et al. Ropinirole for Parkinson's disease. Mov Disord. 2004. ↩︎
Riederer P, Laux G. MAO-B inhibitors for Parkinson's disease. J Neural Transm. 2011. ↩︎
Olanow CW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009. ↩︎
Schapira AH, et al. Safinamide in Parkinson's disease. J Neural Transm. 2017. ↩︎
Antonini A, et al. Continuous dopaminergic stimulation in Parkinson's disease. Therapeutic Advances in Neurological Disorders. 2016. ↩︎
Ferreira JJ, et al. Opicapone for Parkinson's disease. Expert Opin Pharmacother. 2016. ↩︎
Krack P, et al. Long-term follow-up of deep brain stimulation for Parkinson's disease. N Engl J Med. 2003. ↩︎
Volkmann J, et al. Deep brain stimulation for Parkinson's disease. Parkinsonism Relat Disord. 2010. ↩︎
Bronstein JM, et al. Deep brain stimulation for Parkinson's disease. Neurology. 2011. ↩︎
Weaver FM, et al. Randomized trial of deep brain stimulation for Parkinson disease. Neurology. 2009. ↩︎